Song Eun-Ji, Han Kyungsun, Lim Tae-Joong, Lim Sanghyun, Chung Myung-Jun, Nam Myung Hee, Kim Hojun, Nam Young-Do
1Research Group of Healthcare, Korea Food Research Institute, Wanju-gun, 55365 Republic of Korea.
2Department of Food Biotechnology, Korea University of Science and Technology, Daejeon, 34113 Republic of Korea.
EPMA J. 2020 Feb 7;11(1):31-51. doi: 10.1007/s13167-020-00198-y. eCollection 2020 Mar.
Prevention and improvement of disease symptoms are important issues, and probiotics are suggested as a good treatment for controlling the obesity. Human gut microbiota has different community structures. Because gut microbial composition is assumed to be linked to probiotic function, this study evaluated the efficacy of probiotics on obesity-related clinical markers according to gut microbial enterotype.
Fifty subjects with body mass index over 25 kg/m were randomly assigned to either the probiotic or placebo group. Each group received either unlabeled placebo or probiotic capsules for 12 weeks. Body weight, waist circumference, and body composition were measured every 3 weeks. Using computed tomography, total abdominal fat area and visceral fat area were measured. Blood and fecal samples were collected before and after the intervention for biochemical parameters and gut microbial compositions analysis.
Gut microbial compositions of all the subjects were classified into two enterotypes according to / ratio. The fat percentage, blood glucose, and insulin significantly increased in the -rich enterotype of the placebo group. The obesity-related markers, such as waist circumference, total fat area, visceral fat, and ratio of visceral to subcutaneous fat area, were significantly reduced in the probiotic group. The decrease of obesity-related markers was greater in the -rich enterotype than in the -rich enterotype.
Administration of probiotics improved obesity-related markers in obese people, and the efficacy of probiotics differed per gut microbial enterotype and greater responses were observed in the -dominant enterotype.
疾病症状的预防和改善是重要问题，益生菌被认为是控制肥胖的良好治疗方法。人类肠道微生物群具有不同的群落结构。由于肠道微生物组成被认为与益生菌功能有关，本研究根据肠道微生物肠型评估了益生菌对肥胖相关临床指标的疗效。
将50名体重指数超过25kg/m²的受试者随机分为益生菌组或安慰剂组。每组接受未标记的安慰剂或益生菌胶囊，为期12周。每3周测量一次体重、腰围和身体成分。使用计算机断层扫描测量腹部总脂肪面积和内脏脂肪面积。在干预前后采集血液和粪便样本，用于生化参数和肠道微生物组成分析。
根据/比值，所有受试者的肠道微生物组成分为两种肠型。安慰剂组富含的肠型中，脂肪百分比、血糖和胰岛素显著升高。益生菌组中，腰围、总脂肪面积、内脏脂肪以及内脏与皮下脂肪面积之比等肥胖相关指标显著降低。富含的肠型中肥胖相关指标的下降幅度大于富含的肠型。
服用益生菌可改善肥胖人群的肥胖相关指标，益生菌的疗效因肠道微生物肠型而异，在占主导的肠型中观察到更大的反应。
